STUDY GOAL AND OBJECTIVES
This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES
◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
◆ To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
◆ To help company to succeed in a competitive market, and

METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES
The primary information sources include Company Reports, and National Bureau of Statistics of China etc.
Abstract

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decline whereas private hospitals increased rapidly.

During the period from 2011 to late May 2015, the number of private hospitals in China advanced 4,713, with the share up from 38.4% to 49.7%. But in point of revenue, China’s private hospitals just accounted for 10%.

In terms of medical service, between January and May 2015, China saw 1.2152 billion hospital visits, up 5.4% from a year earlier. Although the number of public hospitals occupied only 50.3% of total hospitals, yet the public hospital visits represented up to 89.1%, which was mainly due to the fact that private hospitals are small in scale and have relatively poor treatment level and lower public awareness.

At present, more investment has gone to specialized hospitals, which have captured long-term attention from social capital, hence a great market demand. As of the end of 2014, the number of specialized hospitals in China were expected to reach 5,449, making up 21.4% of the total. Among them, mental hospitals, maternity hospitals, orthopaedic hospitals, stomatological hospitals, and ophthalmic hospitals constitute the mainstay. Tumor hospitals generated the most revenue while beauty hospitals, ophthalmic hospitals, and stomatological hospitals produced relatively higher profit margin.

In recent years, the State has introduced a series of favorable policies designed to encourage private capital into the hospital industry, thus setting off a wave of social capital inrush to medical service. Currently, many private companies including Aier Eye Hospital Group, TC Medical, Mayinglong Pharm, Shanghai Fosun Pharmaceutical (Group), Jinling Pharmaceutical Company Limited, and Phoenix Healthcare Group have ventured into the field of medical service. Among them, Aier Eye Hospital Group and Shanghai Fosun Pharmaceutical (Group) achieved good results in business development. In H1 2015, the medical service revenue for the two companies totaled RMB1.175 billion and RMB674.4 million, respectively.

As China’s largest ophthalmic medical chain institution, Aier Eye Hospital Group have established more than 100 professional ophthalmic hospitals throughout the country, with over 3 million outpatient visits annually. In the past two years, the company set up four industrial merger & acquisition funds used to invest in grand health industry, in the hope of increasing hospital outlets and achieving industrial expansion.

Fosun Pharma specializes in drug manufacturing and research and development meanwhile operating medical service business. In recent years, through self-building, mergers and acquisitions, joint venturing, and affiliation, the company has made continuous expansion in medical service and seen explosive growth in revenue from this field. In 2011-2014, the company’s medical service revenue registered a CAGR of 371.5%.
In 2014, the company participated in the privatization of Chindex International, Inc. ("Chindex"), and upon the completion of the privatization transaction, Fosun Industrial held a 42.927% equity interest and at the same time owned “United Family Hospital”, a high-end brand for healthcare services under Chindex.

The report highlights the followings:

- Overview of China hospital industry, including number of hospitals, revenue, medical service, competition pattern, summary and forecast, etc.;
- Status quo of specialized hospitals in China, including overall operation, development of specialized hospitals of all sorts, etc.;
- Development prediction of China hospital industry, including the impact of medical insurance system and urbanization on hospital industry, etc.;
- Investment in China hospital industry, including related policies, comparison of public and private hospitals, investment opportunities of social capital, and development model of foreign-funded hospitals, etc.;
- Operation, and medical service business of 16 enterprises venturing into hospital industry.
1. Overview of China Hospital Industry
   1.1 Definition
   1.2 Classification
   1.3 Industry Chain

2. Development of China Hospital Industry
   2.1 Overview
   2.1.1 Number of Hospitals
   2.1.2 Distribution
   2.1.3 Total Revenue
   2.1.4 General Hospitals
   2.1.5 Medical Service
   2.1.6 Competition Pattern
   2.1.7 Summary and Forecast

3. Development of Specialized Hospitals in China
   3.1 Overview
   3.1.1 Number of Hospitals
   3.1.2 Revenue
   3.2 Status Quo of Specialized Hospitals of All Kinds
   3.2.1 Ophthalmic Hospital
   3.2.2 Stomatological Hospital
   3.2.3 Orthopedics & Beauty Hospital
   3.2.4 Maternity Hospital Obstetrics and Gynecology Hospital
   3.2.5 Children’s Hospital
   3.2.6 Tumor Hospital

4. Development Forecast of China Hospital Industry
   4.1 Status Quo of China Medical Insurance
   4.1.1 Medical Insurance System
   4.1.2 Medical Insurance Close to Saturation
   4.1.3 Medical Insurance for Serious Illness of Urban and Rural Residents
   4.2 Urbanization Bolsters Development of the Hospital Industry
   4.2.1 Status Quo of Urbanization in China
   4.2.2 Urbanization Expects to Optimize Medical Insurance System
   4.2.3 Trans-regional Medical Insurance Settlement is to be advanced
   4.2.4 Urbanization Incrementation Depends on the Contribution of Medical Insurance System
   4.2.5 Medical Insurance Fund Balance Rate Will See Further Decrease
   4.2.6 Medical Resource Supply of County-Level Hospitals Will Improve
   4.2.7 Urbanization Will Encourage Central Government to Invest in Urban Medical Resources

5. Investment in China Hospital Industry
   5.1 Impetus Given by Policies
   5.2 Comparison of Public and Private Hospitals
   5.2.1 Public Hospitals Play a Leading Role
   5.2.2 Private Hospitals Run with Efficiency
   5.3 Investment Opportunities of Social Capital
   5.3.1 Specialized Medical Field
   5.3.2 General Public Hospitals
   5.4 Development Orientation and Business Model of Foreign Hospitals
   5.4.1 Status Quo of Foreign Hospitals in China
   5.4.2 Development Direction
   5.4.3 Business Practice

6. Major Private Hospitals in China
   6.1 Aier Eye Hospital Group
   6.1.1 Profile
   6.1.2 Operation
   6.1.3 Revenue Structure
   6.1.4 Gross Margin
   6.1.5 R&D and Investment
   6.1.6 Medical Service
   6.1.7 Prediction and Outlook
   6.1.8 TC Medical
   6.1.9 Profile
   6.2 Mayinglong Pharm
   6.2.1 Profile
   6.2.2 Operation
   6.2.3 Revenue Structure
   6.2.4 Gross Margin
   6.2.5 Medical Service
   6.2.6 Prediction and Outlook
   6.2.7 Mayinglong Pharm
   6.3.1 Profile
   6.3.2 Operation
   6.3.3 Revenue Structure
   6.3.4 Gross Margin
   6.3.5 R&D and Investment
   6.4 Shanghai Fosun Pharmaceutical (Group)
   6.4.1 Profile
   6.4.2 Operation
   6.4.3 Revenue Structure
   6.4.4 Gross Margin
   6.4.5 R&D and Investment

---

Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com
China’s Hospital Industry Chain
Number and Increment of Hospitals in China, 2009-2015
Number of Hospitals in China by Level, 2009-2015
Percentage of Hospitals in China by Level as of the end of May 2015
Number of Hospitals in China by Economic Type, 2009-2015
Number of Hospitals in China by Economic Type, 2009-2015
Number of Hospitals in China by Type, 2009-2014
Number of Hospitals in China by Region as of the end of May 2015
Total Revenue and YoY Growth of Hospitals in China 2009-2014
Gross Margin of Hospitals in China, 2009-2014
Revenue Structure of China Hospital Industry by Source, 2013
Revenue Structure of China Hospital Industry by Type, 2013
Average Revenue and YoY Growth of General Hospitals in China 2009-2014
Average Revenue of Each General Hospital in China by Business, 2009-2013
Number of Visits to China’s Hospitals, 2009-2015
Bed Utilization in China’s Hospitals, 2009-2015
Number of Visits to China’s Hospitals by Economic Type, 2012-2015
Structure of Chinese Hospital Visits by Economic Type, Jan.-May, 2015
Number of Visits to China’s Hospitals by Hospital Level, 2012-2015
Structure of Chinese Hospital Visits by Hospital Level, Jan.-May, 2015
Bed Utilization in China’s Hospitals by Hospital Level, 2009-2015
Proportion of Public Medical Institutions and Private Hospitals by Type, 2013
Medical Service Revenue of Major Private Hospitals in China, 2012-2015
Revenue of Major Chinese Private Hospitals, 2014-2018E
Number and Increment of Hospitals in China, 2014-2018E
Number of Specialized Hospitals and % of Total Hospitals in China, 2014-2018E
Revenue and YoY Growth of Hospitals in China, 2014-2018E
Revenue of Hospitals in China by Economic Type, 2014-2018E
Revenue from Specialized Hospitals and % of Total Revenue in China, 2014-2018E
Number of Specialized Hospitals and % of Total Hospitals in China, 2009-2014
Proportion of Specialized Hospitals in China by Economic Type, 2009-2014
Number of Specialized Hospitals in China by Type, 2010-2013
Proportion of Specialized Hospitals in China by Revenue, 2009-2014
Revenue from Specialized Hospitals in China by Type, 2010-2013
Operating Margin of Specialized Hospitals in China by Type, 2010-2013
Number of Ophthalmic Hospitals in China by Economic Type, 2009-2014
Total Revenue and Profits of Ophthalmic Hospitals in China, 2006-2013
Utilization of Hospital Beds and Service Efficiency of Doctors of Ophthalmic Hospitals in China, 2006-2013
Number of Stomatological Hospitals in China by Economic Type, 2009-2014
Total Revenue and Profits of Stomatological Hospitals in China, 2006-2013
Utilization of Hospital Beds and Workload of Doctors of Stomatological Hospitals in China, 2006-2013
Number and Distribution of Major Private Stomatological Medical Institutions and Their Chains in China, 2015
Plastic Surgery & Cosmetic Hospitals in China by Economic Type, 2009-2014
Total Revenue and Profits of Plastic Surgery & Cosmetic Hospitals in China, 2006-2013
Number of Maternity Hospitals in China by Economic Type, 2009-2014
Total Revenue and Profits of Maternity Hospitals in China, 2006-2013
Utilization of Hospital Beds and Workload of Doctors of Maternity Hospitals in China, 2006-2013
Number of Children’s Hospitals in China by Economic Type, 2009-2014
Total Revenue and Profits of Children’s Hospitals in China, 2006-2013
Utilization of Hospital Beds and Workload of Doctors of Children’s Hospitals, 2006-2013
Selected Charts

- Number of Tumor Hospitals in China by Economic Type, 2009-2014
- Total Revenue and Profits of Tumor Hospitals in China, 2006-2013
- Utilization of Hospital Beds and Workload of Doctors of Tumor Hospitals in China, 2006-2013
- Structure of Medical Insurance System in China
- Population Covered under China’s Urban Medical Insurance, 2008-2014
- Urbanization Rate of China, 2000-2014
- China’s Healthcare Expenditure Structure, 2005-2014
- Medical Insurances of China’s Urban Workers and Balance Rate of New Rural Cooperative Medical System, 2005-2014
- Favorable Policies on the Construction of County-Level Hospitals, 2009-2014
- Landmark Events on Social Capitals Flowing to Medical Service Field in China, 1985-2014
- Policies on Social Capitals Flowing to Medical Service Field in China, 2009-2015
- Differences in Policies on China’s Private and Public Hospitals
- Entrustment Chain of Public Hospitals in China
- Revenue and Market Share of Public Hospitals in China, 2008-2014
- Revenue and Market Share of Private Hospitals in China, 2008-2014
- Comparison of China’s Major Medical Service-related Special projects
- Trends towards Marketization of Medical Service System in China
- Reform Mode of Established Property Rights System of Public Hospitals
- Pilot Cases of China’s Social Capitals Contributing to Public Hospital Restructuring, 1999-2015
- Partners and Major Medical Treatment Services of Sino-foreign Joint Ventures in China
- Partners and Major Services of Sino-foreign Joint Ventures in China
- Revenue and Net Income of Aier Eye Hospital Group, 2011-2015
- Net Income of Aier Eye Hospital Group’s Major Subsidiaries, 2015H1
- Revenue of Aier Eye Hospital Group by Business, 2009-2015
- Revenue of Aier Eye Hospital Group by Region, 2009-2014
Selected Charts

- Revenue Structure of Aier Eye Hospital Group by Region, 2009-2014
- Gross Margin of Aier Eye Hospital Group by Business, 2009-2014
- R&D Costs and % of Total Revenue of Aier Eye Hospital Group, 2012-2014
- Medical Service Revenue and % of Total of Aier Eye Hospital Group, 2009-2015
- Revenue and Net Income of Aier Eye Hospital Group, 2014-2018E
- Revenue and Net Income of TC Medical, 2011-2015
- Revenue of TC Medical by Business, 2012-2015
- Revenue of TC Medical by Region, 2012-2015
- Revenue Structure of TC Medical by Region, 2012-2015
- Gross Margin of TC Medical, 2012-2015
- Gross Margin of TC Medical by Business, 2012-2015
- Client Orientation of TC Medical
- Revenue and Net Income of TC Medical's Major Subsidiaries, 2013-2014
- Revenue and Net Income of TC Medical, 2014-2018E
- Revenue and Net Income of Mayinglong Pharm, 2011-2015
- Revenue of Mayinglong Pharm by Product, 2012-2015
- Revenue Structure of Mayinglong Pharm by Product, 2012-2015
- Revenue of Mayinglong Pharm by Region, 2012-2015
- Revenue Structure of Mayinglong Pharm by Region, 2012-2015
- Gross Margin of Mayinglong Pharm by Product, 2012-2015
- R&D Costs and % of Total Revenue of Mayinglong Pharm, 2012-2015
- Key R&D Projects of Mayinglong Pharm, 2015
- Establishment Mode and Equity Structure of Anorectum Hospitals under Mayinglong Pharm
- Revenue and Net Income of Mayinglong Pharm, 2014-2018E
- Revenue and Net Income of Shanghai Fosun Pharmaceutical (Group), 2011-2015
- Revenue and Net Income of Shangh
Selected Charts

- Revenue of Shanghai Fosun Pharmaceutical (Group) by Business, 2011-2015
- Revenue Structure of Shanghai Fosun Pharmaceutical (Group) by Business, 2011-2015
- Revenue of Shanghai Fosun Pharmaceutical (Group) by Region, 2011-2015
- Revenue Structure of Shanghai Fosun Pharmaceutical (Group) by Region, 2011-2015
- Gross Margin of Shanghai Fosun Pharmaceutical (Group) by Business, 2011-2015
- R&D Costs and % of Total Revenue of Shanghai Fosun Pharmaceutical (Group), 2012-2015
- Number and Subscription Amount of Shares through Private Placement of Shanghai Fosun Pharmaceutical (Group), 2015
- Medical Service Revenue and % of Total of Shanghai Fosun Pharmaceutical (Group), 2011-2015
- Revenue and Net Income of Shanghai Fosun Pharmaceutical (Group), 2014-2018E
- Revenue of Jinling Pharmaceutical by Region, 2012-2015
- Revenue Structure of Jinling Pharmaceutical by Region, 2012-2015
- R&D Costs and % of Total Revenue of Jinling Pharmaceutical, 2012-2015
- Medical Service Revenue and % of Total of Jinling Pharmaceutical, 2011-2015
- Revenue and Net Income of Shinva Medical, 2011-2015
- Revenue of Shinva Medical by Product, 2011-2015
- Revenue Structure of Shinva Medical by Product, 2011-2015
- Revenue of Shinva Medical by Region, 2011-2015
- Revenue Structure of Shinva Medical by Region, 2011-2015
- Gross Margin of Shinva Medical by Product, 2011-2015
- R&D Costs and % of Total Revenue of Shinva Medical, 2012-2014
Selected Charts

- Revenue and Net Income of Shinva Medical, 2014-2018E
- Revenue and Net Income of Xi’an International Medical Investment, 2011-2015
- Revenue of Xi’an International Medical Investment by Segment, 2012-2015
- Revenue Structure of Xi’an International Medical Investment by Segment, 2012-2015
- Revenue of Xi’an International Medical Investment by Region, 2011-2015
- Revenue Structure of Xi’an International Medical Investment by Region, 2011-2015
- Medical Service Revenue and % of Total of Xi’an International Medical Investment, 2012-2015
- Revenue and Net Income of Xi’an International Medical Investment, 2011-2015
- Issue Objects for the Private Placement, Their Placement Shares, and Subscription Amount of Xi’an International Medical Investment, 2015
- Revenue and Net Income of Xi’an International Medical Investment, 2014-2018E
- Revenue and Net Income of Inner Mongolia Furui Medical Science, 2011-2015
- Revenue of Inner Mongolia Furui Medical Science by Product, 2011-2015
- Revenue Structure of Inner Mongolia Furui Medical Science by Product, 2011-2015
- Revenue and Net Income of Inner Mongolia Furui Medical Science, 2014-2018E
- Revenue Structure of Wuhan Jianmin Pharmaceutical Groups Corp. by Segment, 2012-2015
- Revenue of Wuhan Jianmin Pharmaceutical Groups Corp. by Segment, 2012-2015
- Revenue Structure of Wuhan Jianmin Pharmaceutical Groups Corp. by Region, 2011-2015
- Revenue of Wuhan Jianmin Pharmaceutical Groups Corp. by Region, 2011-2015
- Revenue and Net Income of Concord Medical Services Holdings Limited, 2011-2015
- Coverage of Service Network of Concord Medical Services Holdings Limited
- Revenue and Net Income of Concord Medical Services Holdings Limited, 2014-2018E
- General Hospital Service Revenue and YoY Growth of Phoenix Healthcare Group, 2011-2015
• Hospital Management Service Revenue Structure of Phoenix Healthcare Group by Hospital, 2014
• Revenue and Net Income of Phoenix Healthcare Group, 2014-2018E
• Revenue and Net Income of Guizhou Yibai Pharmaceutical, 2011-2015
• Medical Service Revenue and % of Total of Guizhou Yibai Pharmaceutical, 2011-2015
• Revenue and Net Income of Guizhou Yibai Pharmaceutical, 2014-2018E
• Revenue and Net Income of Kangmei Pharmaceutical, 2011-2015
• Revenue and Net Income of Kangmei Pharmaceutical, 2014-2018E
• Revenue and Net Income of JNMPT, 2011-2015
• Revenue and Net Income of JNMPT, 2014-2018E
• Revenue and Net Income of China Resources Sanjiu Medical & Pharmaceutical Co., 2011-2015
• Medical Service Revenue and YoY Growth of China Resources Sanjiu Medical & Pharmaceutical Co., 2009-2013
• Parkway Pantai Medical's Centers and Services in China
You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828 / 82601561

<table>
<thead>
<tr>
<th>Party A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name:</td>
</tr>
<tr>
<td>Address:</td>
</tr>
<tr>
<td>Contact Person:</td>
</tr>
<tr>
<td>E-mail:</td>
</tr>
<tr>
<td>Fax</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Party B:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina)</td>
</tr>
<tr>
<td>Address: Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080</td>
</tr>
<tr>
<td>Contact Person: Liao Yan</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:report@researchinchina.com">report@researchinchina.com</a></td>
</tr>
<tr>
<td>Phone: 86-10-82600828</td>
</tr>
<tr>
<td>Fax: 86-10-82601570</td>
</tr>
</tbody>
</table>

| Bank details: | 
| Beneficial Name: Beijing Waterwood Technologies Co., Ltd | 
| Bank Name: Bank of Communications, Beijing Branch | 
| Bank Address: NO.1 jinxiyuan shijicheng, Landianchang, Haidian District, Beijing | 
| Bank Account No #: 110060668012015061217 | 
| Routing No #: 332906 | 
| Bank SWIFT Code: COMMCNSHBJG |

Choose type of format

- PDF (Single user license) ..........2,500 USD
- Hard copy ..........................2,700 USD
- PDF (Enterprisewide license) .........3,900 USD

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via PayPal.

<table>
<thead>
<tr>
<th>Title</th>
<th>Format</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com
About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- **Multi-users market reports**
- **Database-RICDB**
- **Custom Research**
- **Company Search**

RICDB (http://www.researchinchina.com/data/database.html), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at:

Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com